Surge
Innovative fingerprinting of the immune system with AI to holistically improve the perioperative standard-of-care.
- B2B
- saas
- manufacturing
- advertising
- commission
- subscription
- health
- health platform
- pharmaceutical
- biotechnology
- medical devices
- artificial intelligence
- hardware
- deep tech
- dt and ls
- biotechnology
- spinout
- core ai
- radar de l'innovation
- ai applications
- tech for business
- observatoire deeptech
- surgery
- health it
- biotech, medtech and e-health
- nif defense security and resilience
- ai drug discovery
- tech for hospitals and clinics
- tech for medical professionals
- physician support tools
- surgical equipment
- clinical decision support
- biomarkers
- precision medicine
- nif health crisis preparedness
- nif biotech
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $2.2m | Grant | |
| Total Funding | 000k | ||
| USD | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 460 % |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Surge.care is a health-tech startup based in Silicon Valley, led by a team of six individuals from prestigious institutions such as Stanford, Harvard, Sorbonne, and Ecole Polytechnique. The company operates in the healthcare sector, specifically focusing on the development of products and services that enhance the capabilities of healthcare teams.
The company's flagship technology, PreCyte, is the result of a decade-long research. PreCyte is an innovative immunological fingerprinting technology that combines high-resolution exploration of the human immune system with the identification of actionable predictive information. This technology is designed to optimize preventive strategies and aid in the development of new treatments or medical devices.
Surge.care's business model revolves around leveraging their proprietary AI-powered platform to identify reliable immune signatures of specific clinical outcomes. This information is biologically interpretable and clinically actionable, allowing researchers and clinicians to focus on the most impactful interventions.
The company's services are particularly beneficial for surgical units, where postoperative infections are a common and costly complication. With an average cost of $72,000 per postoperative infection, Surge.care's technology can potentially save a surgical unit up to $26 million per year.
In summary, Surge.care is a health-tech company that uses AI and immunological fingerprinting technology to enhance healthcare outcomes, particularly in the area of postoperative care.
Keywords: Health-tech, Silicon Valley, PreCyte, Immunological Fingerprinting, Preventive Strategies, AI-Powered Platform, Clinical Outcomes, Postoperative Infections, Healthcare Teams, Cost-Saving.